UroToday2h
ADSTILADRIN® in Patients With High-Risk, BCG Unresponsive NMIBC
The 2024 ESMO Annual Congress was host to the session Updates in the management of advanced renal cell carcinoma. Dr. Teresa Alonso Gordoa discussed systemic treatment options for the management of ...
UroToday8h
SES AUA 2025: Artificial Intelligence Applications in Prostate Cancer Diagnosis and Treatment
Saikali S, Khosravi P, Gamal A, et al. MP07-02 Detection of Prostate Cancer Extracapsular Extension with MRI Using Deep Learning Methods. J Urol. 2024 May;211 (5S):e105.
UroToday2d
SES AUA 2025: PSA Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Paul Sieber discussing a post hoc analysis ...
UroToday2d
SES AUA 2025: Validation of PAM50 for Predicting Progression in Active Surveillance: Results from the Miami MAST Prospective Clinical Trial
SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Jamie Thomas discussing results from the MAST trial assessing the validation of PAM50 for predicting progression in ...
UroToday3d
SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC
SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Joon Kyung Kim discussing an evaluation of ...
UroToday3d
SES AUA 2025: Germline Testing for Renal Cancers – How Age and Tumor Characteristics Affect Pathogenic Variants
SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...
UroToday3d
SES AUA 2025: Identifying Key Mutations Linked to Metastasis in Clear Cell Renal Cell Carcinoma: A GENIE Database Analysis
The cohort had a median age of 65 years (IQR 53–68), with 74% male and 82% Caucasian. Of the total 808 gene panel, 15 genes were mutated by >5% in the entire cohort, with PBRM1, SETD2, KDM5C, TP53, ...
UroToday4d
Use of biochemical and imaging criteria for selecting patients for prostate biopsy in recurrence risk assessment post-HIFU therapy.
Despite the growing adoption of HIFU treatment for localized prostate cancer (PC), standardized criteria for evaluating success and predicting recurrence remain undefined. Herein, we analyze the ...
UroToday4d
T-cell Engagers in Prostate Cancer.
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new ...
UroToday4d
Establishing cM0 (i+) stage criteria in localized renal cell carcinoma based on postoperative circulating tumor cells monitoring.
The diagnostic criteria for cM0 (i+) stage proposed by American Joint Committee on Cancer (AJCC) in renal cell carcinoma (RCC) still remains unclear. The present study aimed to establish and validate ...
UroToday4d
SES AUA 2025: ENVISION: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single-Arm, Open-Label, Phase 3 Trial
Low grade non-muscle invasive bladder cancer (Ta) confirmed by cystoscopy and cold cup biopsy of the visualized tumor at screening or within 8 weeks before screening Negative voiding cytology for high ...
UroToday4d
SES AUA 2025: Oncologic Efficacy of Reduced versus Standard-Dose BCG for NMIBC
SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for non muscle invasive ...